CO2021016198A2 - Composiciones útiles para el tratamiento de la enfermedad de pompe - Google Patents
Composiciones útiles para el tratamiento de la enfermedad de pompeInfo
- Publication number
- CO2021016198A2 CO2021016198A2 CONC2021/0016198A CO2021016198A CO2021016198A2 CO 2021016198 A2 CO2021016198 A2 CO 2021016198A2 CO 2021016198 A CO2021016198 A CO 2021016198A CO 2021016198 A2 CO2021016198 A2 CO 2021016198A2
- Authority
- CO
- Colombia
- Prior art keywords
- disease
- raav
- pompe
- protein
- treatment
- Prior art date
Links
- 206010053185 Glycogen storage disease type II Diseases 0.000 title abstract 3
- 201000004502 glycogen storage disease II Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 2
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 102000045921 human GAA Human genes 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
Abstract
Se proporciona un virus adenoasociado recombinante (rAAV) útil para tratar la enfermedad por almacenamiento de glucógeno tipo II (enfermedad de Pompe). El rAAV comprende una cápside de AAV que se dirige a células de al menos uno de los músculos, el corazón, el riñón y el sistema nervioso central y que tiene empaquetado allí un genoma de vector que comprende una secuencia de ácido nucleico que codifica una proteína de fusión quimérica que comprende un péptido señal y un péptido de vIGF2 fusionado a una proteína hGAA780I de ácido-α-glucosidasa humana bajo el control de secuencias reguladoras que dirigen su expresión. También se proporcionan métodos para hacer y usar este rAAV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840911P | 2019-04-30 | 2019-04-30 | |
US201962913401P | 2019-10-10 | 2019-10-10 | |
PCT/US2020/030484 WO2020223356A1 (en) | 2019-04-30 | 2020-04-29 | Compositions useful for treatment of pompe disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021016198A2 true CO2021016198A2 (es) | 2022-01-17 |
Family
ID=73029176
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0016198A CO2021016198A2 (es) | 2019-04-30 | 2021-11-29 | Composiciones útiles para el tratamiento de la enfermedad de pompe |
CONC2021/0016200A CO2021016200A2 (es) | 2019-04-30 | 2021-11-29 | Composiciones útiles para el tratamiento de la enfermedad de pompe |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0016200A CO2021016200A2 (es) | 2019-04-30 | 2021-11-29 | Composiciones útiles para el tratamiento de la enfermedad de pompe |
Country Status (15)
Country | Link |
---|---|
US (2) | US20220193207A1 (es) |
EP (2) | EP3980548A4 (es) |
JP (2) | JP2022530833A (es) |
KR (2) | KR20220008280A (es) |
CN (2) | CN114072515A (es) |
AU (2) | AU2020266552A1 (es) |
BR (2) | BR112021021720A2 (es) |
CA (2) | CA3134485A1 (es) |
CL (2) | CL2021002754A1 (es) |
CO (2) | CO2021016198A2 (es) |
IL (2) | IL287522A (es) |
MX (2) | MX2021013364A (es) |
SG (2) | SG11202111380VA (es) |
TW (1) | TW202100541A (es) |
WO (2) | WO2020223362A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4149519A4 (en) * | 2020-05-14 | 2024-06-12 | The Trustees of The University of Pennsylvania | COMPOSITIONS FOR THE TREATMENT OF POMPE DISEASE |
MX2022016528A (es) | 2020-06-17 | 2023-06-02 | Univ Pennsylvania | Composiciones y métodos para el tratamiento de pacientes de terapia génica. |
IL312676A (en) * | 2021-11-12 | 2024-07-01 | Amicus Therapeutics Inc | Gene therapy for the treatment of mucopolysaccharidosis IIIA |
NL2031676B1 (en) * | 2022-04-22 | 2023-11-07 | Univ Erasmus Med Ct Rotterdam | Gene therapy for Pompe Disease |
WO2024003687A1 (en) * | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
WO2024151982A1 (en) * | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Gene therapy constructs for the treatment of pompe disease |
CN116693633B (zh) * | 2023-02-21 | 2023-12-22 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1587923B1 (en) * | 2003-01-22 | 2011-08-24 | Duke University | Improved constructs for expressing lysosomal polypeptides |
US20050244400A1 (en) * | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
CA2669347A1 (en) * | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
WO2009043353A2 (en) * | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
WO2012070014A2 (en) * | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
DK2714752T3 (en) * | 2011-05-27 | 2018-02-26 | Amicus Therapeutics Inc | PROCEDURES FOR THE CONNECTION OF TARGETING PEPTIDES TO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENT OF LYSOSOMAL DISPOSAL DISEASES |
WO2013013019A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Lysosomal polypeptides, methods of making and using |
EP3875593A1 (en) * | 2015-12-11 | 2021-09-08 | California Institute of Technology | Targeting peptides for directing adeno-associated viruses (aavs) |
BR112019004785A2 (pt) * | 2016-09-12 | 2019-06-04 | Genethon | variantes de alfa-glicosidase ácida e usos das mesmas |
EP3293260A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
EP3293259A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
EP3600445A1 (en) * | 2017-03-27 | 2020-02-05 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
-
2020
- 2020-04-29 KR KR1020217038223A patent/KR20220008280A/ko unknown
- 2020-04-29 WO PCT/US2020/030493 patent/WO2020223362A1/en unknown
- 2020-04-29 MX MX2021013364A patent/MX2021013364A/es unknown
- 2020-04-29 AU AU2020266552A patent/AU2020266552A1/en active Pending
- 2020-04-29 BR BR112021021720A patent/BR112021021720A2/pt unknown
- 2020-04-29 JP JP2021565001A patent/JP2022530833A/ja active Pending
- 2020-04-29 CN CN202080049015.0A patent/CN114072515A/zh active Pending
- 2020-04-29 KR KR1020217038231A patent/KR20220004696A/ko unknown
- 2020-04-29 BR BR112021021792A patent/BR112021021792A2/pt unknown
- 2020-04-29 CA CA3134485A patent/CA3134485A1/en active Pending
- 2020-04-29 EP EP20798851.0A patent/EP3980548A4/en active Pending
- 2020-04-29 JP JP2021564730A patent/JP2022530824A/ja active Pending
- 2020-04-29 EP EP20799541.6A patent/EP3963063A4/en active Pending
- 2020-04-29 US US17/606,410 patent/US20220193207A1/en active Pending
- 2020-04-29 AU AU2020266829A patent/AU2020266829A1/en active Pending
- 2020-04-29 WO PCT/US2020/030484 patent/WO2020223356A1/en unknown
- 2020-04-29 CN CN202080048355.1A patent/CN114127275A/zh active Pending
- 2020-04-29 CA CA3134523A patent/CA3134523A1/en active Pending
- 2020-04-29 SG SG11202111380VA patent/SG11202111380VA/en unknown
- 2020-04-29 TW TW109114314A patent/TW202100541A/zh unknown
- 2020-04-29 US US17/606,414 patent/US20220193261A1/en active Pending
- 2020-04-29 MX MX2021013365A patent/MX2021013365A/es unknown
- 2020-04-29 SG SG11202111400TA patent/SG11202111400TA/en unknown
-
2021
- 2021-10-20 CL CL2021002754A patent/CL2021002754A1/es unknown
- 2021-10-20 CL CL2021002755A patent/CL2021002755A1/es unknown
- 2021-10-24 IL IL287522A patent/IL287522A/en unknown
- 2021-10-24 IL IL287523A patent/IL287523A/en unknown
- 2021-11-29 CO CONC2021/0016198A patent/CO2021016198A2/es unknown
- 2021-11-29 CO CONC2021/0016200A patent/CO2021016200A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202100541A (zh) | 2021-01-01 |
MX2021013365A (es) | 2022-01-26 |
CN114072515A (zh) | 2022-02-18 |
EP3980548A1 (en) | 2022-04-13 |
EP3980548A4 (en) | 2023-09-06 |
WO2020223362A1 (en) | 2020-11-05 |
US20220193207A1 (en) | 2022-06-23 |
AU2020266552A1 (en) | 2021-11-11 |
CA3134523A1 (en) | 2020-11-05 |
CL2021002755A1 (es) | 2022-05-27 |
US20220193261A1 (en) | 2022-06-23 |
CL2021002754A1 (es) | 2022-05-27 |
KR20220008280A (ko) | 2022-01-20 |
CO2021016200A2 (es) | 2022-01-17 |
EP3963063A1 (en) | 2022-03-09 |
KR20220004696A (ko) | 2022-01-11 |
SG11202111380VA (en) | 2021-11-29 |
IL287523A (en) | 2021-12-01 |
MX2021013364A (es) | 2022-01-26 |
SG11202111400TA (en) | 2021-11-29 |
CN114127275A (zh) | 2022-03-01 |
CA3134485A1 (en) | 2020-11-05 |
WO2020223356A1 (en) | 2020-11-05 |
IL287522A (en) | 2021-12-01 |
JP2022530824A (ja) | 2022-07-01 |
BR112021021720A2 (pt) | 2021-12-28 |
WO2020223362A8 (en) | 2021-01-14 |
JP2022530833A (ja) | 2022-07-01 |
EP3963063A4 (en) | 2023-09-27 |
AU2020266829A1 (en) | 2021-11-11 |
BR112021021792A2 (pt) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021016198A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
ES2426091T3 (es) | Uso de maquinaria de replicación de AAV para producción de proteína mejorada | |
NZ763018A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
PE20160188A1 (es) | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos | |
RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
BR112021018776A2 (pt) | Vetores de vírus adenoassociado recombinante | |
PE20191261A1 (es) | Composiciones utiles para el tratamiento de atrofia muscular espinal | |
EA202091352A1 (ru) | Генотерапия мукополисахаридоза iiib | |
PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
RU2019142845A (ru) | Вирусная экспрессионная конструкция, содержащая кодирующую последовательность фактора роста фибробластов 21 (fgf21) | |
PE20221254A1 (es) | Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma | |
García‐Olloqui et al. | Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors | |
CO2022017224A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
AR122404A1 (es) | Variantes de cápside y usos de las mismas | |
FI3177313T3 (fi) | Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi | |
EA202192973A1 (ru) | Композиции, полезные для лечения болезни помпе | |
EP2384761B1 (en) | Modified rodent parvovirus capable of propagating and spreading through human gliomas | |
Yap et al. | Expression of target genes by coinfection with replication-deficient viral vectors. | |
RU2022123359A (ru) | Новые капсидные белки аденоассоциированного вируса | |
AR122251A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de krabbe | |
AR126839A1 (es) | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta | |
Shitik et al. | Capsid modifications of adeno-associated virus serotype 2 | |
RU2021124726A (ru) | Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 9 серотипа (AAV9), капсид и вектор на его основе | |
RU2020136195A (ru) | РЕКОМБИНАНТНЫЙ АДЕНОАССОЦИИРОВАННЫЙ ВИРУС, ЯВЛЯЮЩИЙСЯ ГИБРИДОМ СЕРОТИПОВ AAV9 И AAVrh74, С ПОНИЖЕННЫМ ТРОПИЗМОМ К ПЕЧЕНОЧНОЙ ТКАНИ |